Dear Ms. Robbins:

Please refer to your supplemental new drug application (sNDA) dated and received on March 07, 2022, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Augmentin ES-600 (amoxicillin and clavulanate potassium) for oral suspension, 600 mg/42.9 mg per 5 mL.

This “Changes Being Effected” sNDA provides for the revisions to the following sections of the Prescribing Information (PI).

1. **HIGHLIGHTS OF PRESCRIBING INFORMATION** under **INDICATIONS AND USAGE (1)** section: additional revisions were made to update the regulatory required statement for the labeling of systemic antibacterial drug products. **HIGHLIGHTS OF PRESCRIBING INFORMATION** was also updated to reflect changes to the **FULL PRESCRIBING INFORMATION** described below as appropriate.

2. **FULL PRESCRIBING INFORMATION**

   A. The **INDICATIONS AND USAGE (1)** section was revised to change the subheading from “NOTES” to “Limitations of Use”.

   B. The **WARNINGS AND PRECAUTIONS (5)** section was revised to include the **Severe Cutaneous Adverse Reactions (5.2)** subsection. The **ADVERSE REACTIONS (6)** section and the **PATIENT COUNSELING INFORMATION (17)** section were updated to reflect these changes.

   C. The **ADVERSE REACTIONS (6)** section, **Postmarketing Experience (6.2)** subsection, was revised to include aseptic meningitis under **Central Nervous System**.

   D. The **DESCRIPTION (11)** section was updated to add an equivalency statement per *Guidance for Industry: Naming of Drug Products Containing Salt Drug Substances* (June 2015). In addition, the descriptor “trihydrate” was added.
throughout the PI to reflect that amoxicillin exists as the trihydrate form in the drug product formulation.

E. The **HOW SUPPLIED/STORAGE AND HANDLING (16)** section was updated to revise the National Drug Codes (NDC).

The product established name was revised throughout the PI to comply with the USP monograph.

In addition, *Clostridium difficile* was replaced with *Clostridioides difficile* throughout the PI. Furthermore, the term antibiotic(s) was replaced with antibacterial(s) throughout the PI.

Additionally, minor editorial updates have been made throughout the PI.

3. **Container Label**

   A. The established name, the equivalency statement and the NDC were revised accordingly to reflect the changes in the PI.

   B. The container label was revised for the strength statement to describe all active ingredients in the product.

   C. A place to write the reconstitution date was added to the container label to help mitigate the risk of administration of expired medication.

   D. The container label was revised to ensure prominence and readability and to be consistent with Drug Supply Chain Security Act requirements.

**APPROVAL & LABELING**

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

**WAIVER OF ½ PAGE LENGTH REQUIREMENT FOR HIGHLIGHTS**

We are waiving the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of Prescribing Information. This waiver applies to all future supplements containing revised labeling unless we notify you otherwise.
CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.¹ Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry SPL Standard for Content of Labeling Technical Qs and As.²

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

CARTON AND CONTAINER LABELING

Submit final printed container labeling that is identical to the enclosed container labeling as soon as they are available, but no more than 30 days after they are printed. Please submit these labeling electronically according to the guidance for industry Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications. For administrative purposes, designate this submission “Final Printed Carton and Container Labeling for approved NDA 050755/S-024.” Approval of this submission by FDA is not required before the labeling is used.

All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety-related information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety-related information that appears in the revised labeling. Within

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database [https://www.fda.gov/RegulatoryInformation/Guidances/default.htm](https://www.fda.gov/RegulatoryInformation/Guidances/default.htm).

U.S. Food and Drug Administration
Silver Spring, MD 20993
www.fda.gov
7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4).

**PATENT LISTING REQUIREMENTS**

Pursuant to 21 CFR 314.53(d)(2) and 314.70(f), certain changes to an approved NDA submitted in a supplement require you to submit patent information for listing in the Orange Book upon approval of the supplement. You must submit the patent information required by 21 CFR 314.53(d)(2)(i)(A) through (C) and 314.53(d)(2)(ii)(A) and (C), as applicable, to FDA on Form FDA 3542 within 30 days after the date of approval of the supplement for the patent information to be timely filed (see 21 CFR 314.53(c)(2)(ii)). You also must ensure that any changes to your approved NDA that require the submission of a request to remove patent information from the Orange Book are submitted to FDA at the time of approval of the supplement pursuant to 21 CFR 314.53(d)(2)(ii)(B) and 314.53(f)(2)(iv).

**REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Kristine Park, PhD, RAC, Senior Regulatory Health Project Manager, at (301) 796-0471.

Sincerely,

{See appended electronic signature page}

Dmitri Iarikov, MD, PhD
Deputy Director
Division of Anti-Infectives
Office of Infectious Diseases
Center for Drug Evaluation and Research

ENCLOSURES:

- Content of Labeling
  - Prescribing Information
- Container Labeling

U.S. Food and Drug Administration
Silver Spring, MD 20993
www.fda.gov
This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

DMITRI IARIKOV
06/30/2022 06:52:59 PM